NO20092741L - DR6-antagonister og anvendelse derav ved behandling av neurologiske forstyrrelser - Google Patents

DR6-antagonister og anvendelse derav ved behandling av neurologiske forstyrrelser

Info

Publication number
NO20092741L
NO20092741L NO20092741A NO20092741A NO20092741L NO 20092741 L NO20092741 L NO 20092741L NO 20092741 A NO20092741 A NO 20092741A NO 20092741 A NO20092741 A NO 20092741A NO 20092741 L NO20092741 L NO 20092741L
Authority
NO
Norway
Prior art keywords
antagonists
treatment
neurological disorders
antibodies
mammalian
Prior art date
Application number
NO20092741A
Other languages
English (en)
Inventor
Marc Tessier-Lavigne
Anatoly Nikolaev
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of NO20092741L publication Critical patent/NO20092741L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Fremgangsmåter og preparater som omfatter DR6-antagonister for anvendelse ved behandling av neurologiske forstyrrelser, innbefattet Alzheimers sykdom, tilveiebringes. DR6-antagonistene omfatter anti-APP-antistoffer, anti-DR6-antistoffer, DR6-immunadhesiner og DR6-varianter (og fusjonsproteiner derav) som fremmer vekst, regenerasjon eller overlevelse av pattedyrneuronceller eller neuronalt pattedyrvev.
NO20092741A 2006-12-22 2009-07-21 DR6-antagonister og anvendelse derav ved behandling av neurologiske forstyrrelser NO20092741L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87152806P 2006-12-22 2006-12-22
US90084807P 2007-02-12 2007-02-12
PCT/US2007/088521 WO2008080045A2 (en) 2006-12-22 2007-12-21 Dr6 antibodies inhibiting the binding of dr6 to app, and uses thereof in treating neurological disorders

Publications (1)

Publication Number Publication Date
NO20092741L true NO20092741L (no) 2009-09-21

Family

ID=39535220

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20092741A NO20092741L (no) 2006-12-22 2009-07-21 DR6-antagonister og anvendelse derav ved behandling av neurologiske forstyrrelser

Country Status (19)

Country Link
US (1) US20100203044A1 (no)
EP (1) EP2094732A2 (no)
JP (1) JP2010514700A (no)
KR (1) KR20090094854A (no)
AR (1) AR064501A1 (no)
AU (1) AU2007336770A1 (no)
BR (1) BRPI0719459A2 (no)
CA (1) CA2671903A1 (no)
CL (1) CL2007003793A1 (no)
CO (1) CO6210755A2 (no)
MX (1) MX2009006685A (no)
NO (1) NO20092741L (no)
NZ (1) NZ577436A (no)
PE (1) PE20081546A1 (no)
RU (1) RU2009128039A (no)
SG (1) SG177924A1 (no)
TW (1) TW200844113A (no)
WO (1) WO2008080045A2 (no)
ZA (1) ZA201004219B (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2744043A1 (en) * 2008-11-25 2010-06-03 Biogen Idec Ma Inc. Use of dr6 and p75 antagonists to promote survival of cells of the nervous system
TW201034684A (en) * 2009-02-18 2010-10-01 Genentech Inc Method for inhibiting neurodegeneration
RU2012124093A (ru) * 2009-11-12 2013-12-20 Дженентек, Инк. Способ увеличения плотности дендритных шипиков
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9783602B2 (en) 2010-12-01 2017-10-10 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US20120238465A1 (en) * 2011-03-17 2012-09-20 Joseph Audie Drug screening target for alzheimer's disease and method of screening potential drugs
CN102708565A (zh) * 2012-05-07 2012-10-03 深圳市贝尔信智能系统有限公司 一种前景检测的方法、装置和系统
EP3058371B1 (en) 2013-10-14 2021-06-16 Indiana University Research and Technology Corporation Use of acamprosate to modulate erk 1-2 activation in animal models for fxs and asd and individuals diagnosed with fxs and asd
WO2015076282A1 (ja) 2013-11-20 2015-05-28 国立大学法人北海道大学 免疫制御剤
EP3116895A4 (en) * 2014-03-12 2017-08-16 Temple University Of The Commonwealth System Of Higher Education Dr6 receptor mediates the leukemia differentiation activity of angiocidin: a potent anti-tumor peptide
KR102616160B1 (ko) 2015-03-16 2023-12-22 리제너론 파마슈티칼스 인코포레이티드 저하된 상위 및 하위 운동 뉴런 기능 및 감각 지각을 나타내는 비-인간 동물
US11046746B2 (en) * 2015-03-26 2021-06-29 Suzhou Auzone Biological Technology Co., Ltd Method of treatment of cerebral amyloid angiopathy with P75ECD peptide and/or P75ECD-FC fusion protein
MX2018013484A (es) * 2016-05-06 2019-08-12 Abbvie Stemcentrx Llc Nuevos anticuerpos anti-tnfrsf21 y modos de uso.
KR102351126B1 (ko) * 2019-12-03 2022-01-13 재단법인대구경북과학기술원 App 및 mdga1 단백질 상호작용 억제제를 포함하는 약학적 조성물 및 이를 이용한 스크리닝 방법

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3702789A1 (de) * 1987-01-30 1988-08-18 Bayer Ag Vorlaeuferprotein des apc-polypeptids, dafuer codierende dna und diagnostische verwendung der dna und des proteins
EP1132471A3 (de) * 1989-09-12 2001-11-28 F. Hoffmann-La Roche Ag TNF-bindende Proteine
EP0527823A1 (en) * 1990-04-24 1993-02-24 The Regents Of The University Of California Purification, detection and methods of use of protease nexin-2
US5213962A (en) * 1990-04-24 1993-05-25 The Regents Of The University Of California Purification, detection and methods of use of protease Nexin-2
US5716805A (en) * 1991-10-25 1998-02-10 Immunex Corporation Methods of preparing soluble, oligomeric proteins
DE69227380T3 (de) * 1991-11-12 2007-01-11 Prana Biotechnology Ltd., South Melbourne Verfahren zur bestimmung und behandlung von alzheimer-krankheit
CA2086165A1 (en) * 1992-04-09 1993-10-10 Paul P. Tamburini Diagnostic assay for alzheimer's disease based on the proteolysis of alzheimer's precursor protein
US5441870A (en) * 1992-04-15 1995-08-15 Athena Neurosciences, Inc. Methods for monitoring cellular processing of β-amyloid precursor protein
US6013476A (en) * 1997-04-02 2000-01-11 Smithkline Beecham Corporation DNA encoding tumor necrosis related receptor TR7
US6358508B1 (en) 1997-06-11 2002-03-19 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor TR9
US6949358B1 (en) * 1997-06-11 2005-09-27 Human Genome Sciences, Inc. Human tumor necrosis factor receptor TR9
US7378507B2 (en) * 1997-09-18 2008-05-27 Genentech, Inc. PRO217 polypeptides
US6194151B1 (en) * 1997-09-26 2001-02-27 Millenium Pharmaceuticals, Inc. Molecules of the TNF receptor superfamily and uses therefor
FR2778858B1 (fr) * 1998-05-20 2000-06-16 Oreal Emulsion e/h/e stable et son utilisation comme composition cosmetique et/ou dermatologique
US6916907B1 (en) * 1998-10-23 2005-07-12 Curagen Corporation Nucleic acids encoding osteoprotegern-like proteins and methods of using same
US6423494B1 (en) * 1999-03-25 2002-07-23 Millennium Pharmaceuticals, Inc. DR6 and uses thereof
AT5874U1 (de) * 2000-12-29 2003-01-27 Bioorg Bv Pharmazeutische zubereitungen enthaltend amlodipinmaleat
US7241570B2 (en) * 2001-03-23 2007-07-10 University Of Utah Research Foundation Method of screening for agents that regulate the shedding of membrane bound proteins and methods of use
CA2504349A1 (en) * 2001-11-02 2003-05-15 Diagenics International Corporation Monoclonal antibodies specific for beta-amyloid
WO2003040183A2 (en) * 2001-11-09 2003-05-15 The Genetics Company, Inc Compounds for the diagnosis/prevention/treatment of alzheimer's disease
WO2003051290A2 (en) * 2001-12-17 2003-06-26 Eli Lilly And Company Treating b-cell mediated diseases by modulating dr6 activity
EP1444989A1 (en) * 2003-02-07 2004-08-11 Giorgio Dr. Stassi Sensitizing cells for apoptosis by selectively blocking cytokines
EP1447093A1 (en) 2003-02-14 2004-08-18 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Inhibition of the CD95 ligand/receptor system for the treatment of neurological disorders and injuries
AT500483B1 (de) * 2004-07-13 2006-01-15 Mattner Frank Dr Set zur vorbeugung oder behandlung der alzheimer'schen erkrankung
ES2301280A1 (es) * 2005-05-16 2008-06-16 Fina Biotech S.L.U. Metodo para diagnosticar la enfermedad de alzheimer.
US20100099609A1 (en) * 2008-07-28 2010-04-22 Buck Institute For Age Research eAPP AND DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE
RU2012124093A (ru) * 2009-11-12 2013-12-20 Дженентек, Инк. Способ увеличения плотности дендритных шипиков

Also Published As

Publication number Publication date
CL2007003793A1 (es) 2008-07-25
RU2009128039A (ru) 2011-01-27
JP2010514700A (ja) 2010-05-06
AR064501A1 (es) 2009-04-08
CO6210755A2 (es) 2010-10-20
ZA201004219B (en) 2013-02-27
US20100203044A1 (en) 2010-08-12
NZ577436A (en) 2012-05-25
SG177924A1 (en) 2012-02-28
AU2007336770A1 (en) 2008-07-03
CA2671903A1 (en) 2008-07-03
MX2009006685A (es) 2009-07-27
PE20081546A1 (es) 2008-12-22
EP2094732A2 (en) 2009-09-02
WO2008080045A3 (en) 2008-09-12
TW200844113A (en) 2008-11-16
KR20090094854A (ko) 2009-09-08
WO2008080045A2 (en) 2008-07-03
BRPI0719459A2 (pt) 2014-02-04

Similar Documents

Publication Publication Date Title
NO20092741L (no) DR6-antagonister og anvendelse derav ved behandling av neurologiske forstyrrelser
DE602005025106D1 (de) Methoden zur medikamentenaufspürung auf der basis von in vitro differenzierten zellen
NO20083324L (no) Multisykliske aminosyrederivater og anvendelse derav
EA201590833A1 (ru) Антитела для лечения и профилактики болезни альцгеймера и их применение
WO2006060314A3 (en) Generation of replication competent viruses for therapeutic use
ATE482213T1 (de) Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine
AU2005253776A8 (en) Screening methods using c-Abl, Fyn and Syk in combination with tau protein
WO2002064748A8 (en) Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof
DE602004014117D1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
WO2006105252A3 (en) Diagnosis of chronic pulmonary obstructive disease and monitoring of therapy using gene expression analysis of peripheral blood cells
IL177015B (en) Isolated human rpe cells and their use for the treatment of retinal degenerative diseases
WO2005063820A3 (en) Il-7 fusion proteins
DE602005006990D1 (de) Wiederherstellung zerstörten gewebes mit hilfe von multipotenten zellen
WO2005115548A3 (en) Treating depressive disorders with carbonic anhydrase activators
WO2005046570A3 (en) Human stem cell materials and methods
WO2006082304A3 (fr) Nouveaux peptides interagissant avec les membres anti-apoptotiques de la famille de proteines bcl-2 et utilisations
WO2004044168A8 (en) Genetically encoded fluorescent reporters of kinase, methyltransferase, and acetyl-transferase activities
WO2008034016A3 (en) Assays for detecting native-state proteins and identifying compounds that modulate the stability of native-state proteins
ATE359508T1 (de) Screening-verfahren unter verwendung von zebrafisch und der blut-hirn-schranke
DE602006013143D1 (de) Verfahren zum nachweis aggregatbildender zirkulierender proteinformen und mittel zum einfangen gebildeter aggregate
DE602005013650D1 (de) Proteinhydrolysat zur behandlung von müdigkeit
WO2002092013A3 (en) Methods for treating liver disease and liver damage with growth hormone and foxm1b
ATE485377T1 (de) Das überleben dopaminerger neuronen fördernde faktoren und deren verwendungen
DE602006008460D1 (de) NEUES Aß-BINDUNGSPROTEIN UND DESSEN PEPTIDDERIVATE SOWIE VERWENDUNGEN DAVON
WO2005074972A3 (en) Treatment of conditions involving dopaminergic neuronal degeneration using nogo receptor antagonists

Legal Events

Date Code Title Description
RE Reestablishment of rights (par. 72 patents act)
FC2A Withdrawal, rejection or dismissal of laid open patent application